Sahm Adrangi – Founder Of the Kerrisdale Capital Management LLC,

Sahm Adrangi is the founder of the Kerrisdale Capital Management LLC, a company that was launched in the year 2009 and specializes in long-term value investments and event-driven situations. The firm has special interests in stock markets and does intensive research about some misconceptions that have rocked stock exchange for the longest time.

Sahm Adrangi took center stage soon after launching his company and became a respected public figure in investment banking. One of his greatest achievements was unearthing fraudulent schemes by some Chinese companies. SEC used his research to prosecute a number of Chinese companies involved in the scam. He is also a frequent guest speaker in several banking and investment seminars and conferences. Such investor conferences include the Sohn Conference and Activist Investor Conference. Sahm Adrangi has been featured in the wall street journal and the New York Times severally.

 

 

Sahm Adrangi has also been instrumental in offering advisory opinions to creditors on how to do bankruptcy proceedings. This includes bank debt holders, committees and bondholders as well. He also has come to the rescue of bankrupt companies that are on the blink of sinking. Prior to founding his company, he was previously working with the Deutsche Bank where he was very integral in structuring high yield bonds and the chapter 11 exit financings.

Mr. Adrangi has a very impressive education background having pursued a bachelor of Arts in Economics from the Yale University. He has attended several other mini-courses in this field and continues to make strides in investment banking. Adrangi currently stands out as one of the most valuable assets of his company. Having stood by it in even the most turbulent financial times, he is sure that the company will thrive. Presently, he has over $300 milllion worth of assets under his management. This is quite a large portfolio for such a young company.

https://endpts.com/kerrisdales-sahm-adrangi-leads-a-brutal-new-biotech-short-attack-as-trial-results-loom/

Leave a Reply

Your email address will not be published. Required fields are marked *